Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's leading conglomerate Samsung Group is following in the footsteps of Korea's biosimilar front-runner Celltrion in beginning its biopharmaceutical journey as a contract manufacturing organization via a joint venture announced Jan. 25 with multinational contract research organization Quintiles Transnational Corp.
You may also be interested in...
Korea’s Celltrion Dismisses As Rumor Reports That AstraZeneca, Roche And Teva Are Interested Buyers
Celltrion reveals little about the progress of Chairman Seo Jung-jin’s share sell-off as the company’s clinical development moves forward on a Rituxan biosimilar.
Korea’s CJ CheilJedang Corp. Under Police Investigation For Rebates
Probes into CJ and Dong-A signal Korea’s anti-rebate stance won’t stop anytime soon.
Samsung and Biogen Idec Launch Biosimilar Joint Venture
Samsung Bioepis' board of trustees voted a Samsung executive to serve as CEO.